BridgeBio Pharma

BBIO · NASDAQ

$67.55−$0.39 (−0.57%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $67.94

BBIO analyst rating

BuyConsensus of 22 analysts over the last 12 months. 91% rate it a buy.

Strong buy0
Buy20
Hold2
Underperform0
Sell0

12-month price target · 22 analysts

Average $111.25 (+64.7% upside)

Low: $80.80
Now: $67.55
High: $164.85

Upgrades and downgrades

The latest rating actions, newest first

BBIO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Oct 19, 2026	Maintains	Neutral	$94.00 → $91.00	39%
Piper Sandler	Oct 19, 2026	Maintains	Overweight	$115.00 → $120.00	40%
UBS	Oct 15, 2026	Initiates	Buy	$82.00 → $92.00	69%
Barclays	Oct 7, 2026	Maintains	Overweight	$157.00 → $156.00	45%
HC Wainwright & Co.	Sep 10, 2026	Maintains	Buy	$120.00	43%
HC Wainwright & Co.	Sep 2, 2026	Maintains	Buy	$120.00	43%
Mizuho	Sep 1, 2026	Maintains	Outperform	$96.00 → $110.00	40%
Truist Securities	Aug 12, 2026	Maintains	Buy	$102.00 → $107.00	36%
Canaccord Genuity	Aug 12, 2026	Maintains	Buy	$104.00 → $106.00	41%
JP Morgan	Aug 12, 2026	Maintains	Overweight	$100.00 → $111.00	48%

The case for and against

Updated Oct 14, 2026

Bull case

BridgeBio Pharma is attractive because its lead franchise Attruby is already generating meaningful commercial traction, with Q2 US sales of $222MM, up 23% sequentially and 211% year over year, while its long patent runway should support durable growth in ATTR-CM. The bullish view is further reinforced by a near-term multi-product catalyst stack: ribitol, encaleret, and infigratinib each have advanced regulatory progress, strong clinical readouts, and address sizeable orphan markets with limited or no approved therapies. Infigratinib’s oral profile versus injectable competitors, alongside favorable exploratory PROPEL 3 data and BridgeBio’s improved capital position from the $1B preferred equity deal, strengthens confidence in commercialization and a clear path toward profitability by the end of 2027.

Bear case

BridgeBio Pharma is viewed negatively because its value depends heavily on a narrow set of late-stage assets, while multiple programs still face substantial clinical, regulatory, and commercialization risk, including potential failures in safety, efficacy, or approval filings. The company also carries roughly $1.9B in debt, limited cash relative to ongoing launch and development needs, and covenant constraints that could strain operations if Attruby or other candidates underperform, especially with competition from Pfizer’s Vyndaqel/Vyndamax and BioMarin’s Voxzogo. Although BridgeBio reported $720MM of cash, cash equivalents, and short-term restricted cash at Q2 after raising $1B of preferred equity and $633MM of 2033 convertible notes, persistent burn, pricing pressure, and possible dilution leave the balance sheet and equity story vulnerable.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.